207 related articles for article (PubMed ID: 31067495)
1. Nanostructured clay particles supplement orlistat action in inhibiting lipid digestion: An in vitro evaluation for the treatment of obesity.
Joyce P; Dening TJ; Meola TR; Gustafsson H; Kovalainen M; Prestidge CA
Eur J Pharm Sci; 2019 Jul; 135():1-11. PubMed ID: 31067495
[TBL] [Abstract][Full Text] [Related]
2. Spray Dried Smectite Clay Particles as a Novel Treatment against Obesity.
Dening TJ; Joyce P; Kovalainen M; Gustafsson H; Prestidge CA
Pharm Res; 2018 Dec; 36(1):21. PubMed ID: 30519891
[TBL] [Abstract][Full Text] [Related]
3. Inorganic surface chemistry and nanostructure controls lipolytic product speciation and partitioning during the digestion of inorganic-lipid hybrid particles.
Dening TJ; Joyce P; Webber JL; Beattie DA; Prestidge CA
J Colloid Interface Sci; 2018 Dec; 532():666-679. PubMed ID: 30121519
[TBL] [Abstract][Full Text] [Related]
4. Nanostructured Montmorillonite Clay for Controlling the Lipase-Mediated Digestion of Medium Chain Triglycerides.
Dening TJ; Joyce P; Rao S; Thomas N; Prestidge CA
ACS Appl Mater Interfaces; 2016 Dec; 8(48):32732-32742. PubMed ID: 27934188
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers.
Carrière F; Renou C; Ransac S; Lopez V; De Caro J; Ferrato F; De Caro A; Fleury A; Sanwald-Ducray P; Lengsfeld H; Beglinger C; Hadvary P; Verger R; Laugier R
Am J Physiol Gastrointest Liver Physiol; 2001 Jul; 281(1):G16-28. PubMed ID: 11408251
[TBL] [Abstract][Full Text] [Related]
6. Slowing down lipolysis significantly enhances the oral absorption of intact solid lipid nanoparticles.
Yu Z; Fan W; Wang L; He H; Lv Y; Qi J; Lu Y; Wu W
Biomater Sci; 2019 Oct; 7(10):4273-4282. PubMed ID: 31407729
[TBL] [Abstract][Full Text] [Related]
7. Does the commonly used pH-stat method with back titration really quantify the enzymatic digestibility of lipid drug delivery systems? A case study on solid lipid nanoparticles (SLN).
Heider M; Hause G; Mäder K
Eur J Pharm Biopharm; 2016 Dec; 109():194-205. PubMed ID: 27789354
[TBL] [Abstract][Full Text] [Related]
8. Engineering intelligent particle-lipid composites that control lipase-mediated digestion.
Joyce P; Gustafsson H; Prestidge CA
Adv Colloid Interface Sci; 2018 Oct; 260():1-23. PubMed ID: 30119842
[TBL] [Abstract][Full Text] [Related]
9. Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis.
Point V; Bénarouche A; Zarrillo J; Guy A; Magnez R; Fonseca L; Raux B; Leclaire J; Buono G; Fotiadu F; Durand T; Carrière F; Vaysse C; Couëdelo L; Cavalier JF
Eur J Med Chem; 2016 Nov; 123():834-848. PubMed ID: 27543878
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
11. Colloidal aspects of digestion of Pickering emulsions: Experiments and theoretical models of lipid digestion kinetics.
Sarkar A; Zhang S; Holmes M; Ettelaie R
Adv Colloid Interface Sci; 2019 Jan; 263():195-211. PubMed ID: 30580767
[TBL] [Abstract][Full Text] [Related]
12. Orlistat-loaded solid SNEDDS for the enhanced solubility, dissolution, and in vivo performance.
Kim DH; Kim JY; Kim RM; Maharjan P; Ji YG; Jang DJ; Min KA; Koo TS; Cho KH
Int J Nanomedicine; 2018; 13():7095-7106. PubMed ID: 30464461
[TBL] [Abstract][Full Text] [Related]
13. Using the reversible inhibition of gastric lipase by Orlistat for investigating simultaneously lipase adsorption and substrate hydrolysis at the lipid-water interface.
Bénarouche A; Point V; Carrière F; Cavalier JF
Biochimie; 2014 Jun; 101():221-31. PubMed ID: 24508576
[TBL] [Abstract][Full Text] [Related]
14. Nanoemulsified orlistat-embedded multi-unit pellet system (MUPS) with improved dissolution and pancreatic lipase inhibition.
Sangwai M; Sardar S; Vavia P
Pharm Dev Technol; 2014 Feb; 19(1):31-41. PubMed ID: 23259606
[TBL] [Abstract][Full Text] [Related]
15. Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition.
Dolenc A; Govedarica B; Dreu R; Kocbek P; Srcic S; Kristl J
Int J Pharm; 2010 Aug; 396(1-2):149-55. PubMed ID: 20540997
[TBL] [Abstract][Full Text] [Related]
16. Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size.
Suter PM; Marmier G; Veya-Linder C; Hänseler E; Lentz J; Vetter W; Otvos J
Atherosclerosis; 2005 May; 180(1):127-35. PubMed ID: 15823285
[TBL] [Abstract][Full Text] [Related]
17. In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract.
Jannin V; Dellera E; Chevrier S; Chavant Y; Voutsinas C; Bonferoni C; Demarne F
Drug Dev Ind Pharm; 2015; 41(10):1582-8. PubMed ID: 25342478
[TBL] [Abstract][Full Text] [Related]
18. The role of porous nanostructure in controlling lipase-mediated digestion of lipid loaded into silica particles.
Joyce P; Tan A; Whitby CP; Prestidge CA
Langmuir; 2014 Mar; 30(10):2779-88. PubMed ID: 24552363
[TBL] [Abstract][Full Text] [Related]
19. Milk lipid digestion in the neonatal dog: the combined actions of gastric and bile salt stimulated lipases.
Iverson SJ; Kirk CL; Hamosh M; Newsome J
Biochim Biophys Acta; 1991 Apr; 1083(1):109-19. PubMed ID: 2031934
[TBL] [Abstract][Full Text] [Related]
20. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
